Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
Abstract Objectives Due to the increase of type 2 diabetes (T2D), the number of patients in treatment with multiple anti-diabetic agents is increased. According to the recent recommendation of treatment guidelines, sodium-glucose cotransporter 2 (SGLT2) inhibitors would be used as additional treatme...
Main Authors: | Makoto Fujiwara, Masaru Shimizu, Yuko Maejima, Kenju Shimomura |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-03-01
|
Series: | BMC Research Notes |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13104-022-06010-6 |
Similar Items
-
Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review
by: Makoto Fujiwara, et al.
Published: (2023-12-01) -
Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
by: Annamaria Mascolo, et al.
Published: (2023-11-01) -
Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus
by: Mirella Czapska, et al.
Published: (2018-12-01) -
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
by: Magdalena Złotek, et al.
Published: (2023-11-01) -
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
by: Mariusz Dąbrowski
Published: (2021-02-01)